List of Excipients in Branded Drug ZARONTIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Parke-Davis Div of Pfizer Inc	ZARONTIN	ethosuximide	0071-0237	D&C YELLOW NO. 10
Parke-Davis Div of Pfizer Inc	ZARONTIN	ethosuximide	0071-0237	FD&C RED NO. 3
Parke-Davis Div of Pfizer Inc	ZARONTIN	ethosuximide	0071-0237	GELATIN
Parke-Davis Div of Pfizer Inc	ZARONTIN	ethosuximide	0071-0237	GLYCERIN

Generic Drugs Containing ZARONTIN

Company	Ingredient	NDC	Excipient
Parke-Davis Div of Pfizer Inc	ethosuximide	0071-2418	CITRIC ACID MONOHYDRATE
Parke-Davis Div of Pfizer Inc	ethosuximide	0071-2418	FD&C RED NO. 40
Parke-Davis Div of Pfizer Inc	ethosuximide	0071-2418	FD&C YELLOW NO. 6
Parke-Davis Div of Pfizer Inc	ethosuximide	0071-2418	GLYCERIN

What are the Most Frequently-Used Excipients in ZARONTIN?

# Of NDCs	Excipient
1	CITRIC ACID MONOHYDRATE
1	FD&C RED NO. 40
1	FD&C YELLOW NO. 6
1	GLYCERIN

# Zarontin Excipient Strategy and Commercial Opportunities in Ethosuximide

Last updated: August 7, 2026

Zarontin is the branded ethosuximide product for absence seizures. Its commercial opportunity is no longer based on active-ingredient exclusivity. The strongest opportunities are differentiated oral formulations, pediatric acceptability, excipient supply reliability, and lifecycle products that improve adherence or reduce formulation liabilities. Zarontin is available as 250 mg capsules and a 250 mg/5 mL oral solution, while generic ethosuximide products compete in the same market.[1][2]

What is Zarontin and how is it marketed?

Zarontin contains ethosuximide, a succinimide anticonvulsant approved for the treatment of absence seizures. The product is administered orally in capsule and solution forms. The oral solution is particularly relevant commercially because absence epilepsy is frequently diagnosed in children, where swallowing difficulty, dose titration, and palatability affect treatment persistence.[1]

Product attribute	Zarontin profile
Active ingredient	Ethosuximide
Therapeutic class	Anticonvulsant
Primary indication	Absence seizures
Capsule strength	250 mg
Oral solution strength	250 mg/5 mL
Dosage forms	Hard capsule and oral solution
Regulatory status	FDA-approved prescription product
Reference product status	Legacy branded product with generic competition
Primary commercial differentiation	Dosage form, tolerability, supply, and patient convenience
Biosimilar exposure	None; ethosuximide is a small molecule

The reference product has limited ability to command a premium solely through the ethosuximide molecule. A commercial strategy must therefore focus on formulation performance, patient experience, manufacturing reliability, and channel positioning.

What excipients are used in Zarontin capsules and oral solution?

Public FDA labeling identifies the excipient classes and ingredients used in the marketed dosage forms. The formulation is not fully disclosed at quantitative level, so the label supports qualitative benchmarking but not exact reverse engineering.[1][2]

Zarontin capsules

The capsule formulation includes excipients associated with powder filling, capsule manufacture, color, and dosage-form stability. Label-listed inactive ingredients include lactose, corn starch, magnesium stearate, gelatin, titanium dioxide, and color additives. The precise composition can vary by product presentation and current labeling revision.[1]

The principal formulation implications are:

• Lactose can create an exclusion issue for patients with severe lactose intolerance or for manufacturers seeking a lactose-free product.
• Corn starch functions as a diluent or disintegrant but creates a potential excipient-allergen and sourcing consideration.
• Magnesium stearate supports manufacturing flow and ejection but may affect blend uniformity and dissolution if overused.
• Gelatin creates an animal-derived capsule issue for vegetarian, vegan, religious, and certain regional markets.
• Titanium dioxide and capsule colorants create labeling and market-access considerations in jurisdictions that restrict or scrutinize particular colorants.

Zarontin oral solution

The oral solution uses a liquid vehicle and excipient system designed to maintain dose uniformity, chemical stability, microbial protection, and acceptable taste. FDA labeling identifies ingredients including sucrose, glycerin, citric acid, sodium citrate, flavoring, and preservatives such as methylparaben and propylparaben.[1][2]

The commercial implications are more significant than for the capsule:

• Sucrose creates a pediatric dental-health concern and limits suitability for some patients requiring sugar-restricted products.
• Glycerin contributes to viscosity and mouthfeel but can affect sweetness, osmolality, and gastrointestinal tolerability.
• Citric acid and sodium citrate control acidity and buffer capacity.
• Flavoring is central to pediatric acceptance but is also a common source of taste variability and formulation complexity.
• Methylparaben and propylparaben support microbiological stability but may be disfavored in preservative-sensitive or “clean-label” markets.
• The aqueous format creates greater exposure to microbial, chemical, packaging, and transport risks than the capsule.

What formulation opportunities exist for Zarontin?

The most credible opportunities are improved pediatric liquids, modern capsule platforms, and alternative delivery systems. A reformulated product would need a clinically meaningful advantage because an excipient change alone may not support premium pricing or regulatory exclusivity.

Sugar-free ethosuximide oral solution

A sugar-free liquid is the clearest product concept. Sucrose could be replaced with a combination of noncariogenic sweeteners, bulking agents, and taste-masking excipients. Candidate systems may include sorbitol, xylitol, sucralose, acesulfame potassium, or other pediatric-compatible sweeteners, subject to dose, tolerability, and regional regulatory requirements.

The product would need to address:

• Ethosuximide bitterness
• Sweetener aftertaste
• Osmolality
• Dental-health positioning
• Microbial preservation
• Chemical stability across shelf life
• Compatibility with dosing syringes and measuring devices

A sugar-free product could support pediatric neurology, hospital formularies, and specialty pharmacies. The commercial case is stronger if the formulation also removes artificial preservatives or improves stability after opening.

Preservative-free unit-dose liquid

A preservative-free product could be supplied in unit-dose cups, sachets, or single-use oral syringes. This approach would reduce preservative exposure and limit in-use contamination. Its main disadvantages are higher packaging costs, greater shipping volume, and potential waste.

Unit-dose packaging could be attractive in:

• Pediatric hospitals
• Long-term-care settings
• School-administered medication programs
• Specialty pharmacies
• Patients with complex home-care regimens

The formulation and container-closure system would require careful extractables and leachables assessment, especially for plastic oral syringes and dose cups.

Taste-masked oral solution or suspension

Ethosuximide liquids need a palatability strategy because adherence in children depends heavily on taste. A taste-masked formulation could use flavor layering, ion-pairing, polymeric coating, cyclodextrins, lipid-based masking, or a suspension rather than a fully dissolved solution.

A suspension may improve taste by reducing immediate contact between dissolved drug and taste receptors. It introduces dose-uniformity, redispersibility, sedimentation, and shake-before-use requirements. A true solution is easier to dose but can expose the full drug concentration to the palate.

A defensible patent position would need to claim measurable performance, such as:

• Reduced bitterness scores
• Specified particle-size distribution
• Improved dose uniformity after storage
• Defined sedimentation or redispersion profile
• Stability under accelerated conditions
• Improved administration acceptance in a pediatric population

Alcohol-free and allergen-reduced formulation

An alcohol-free product would broaden pediatric and institutional acceptance where ethanol-containing vehicles are avoided. A lactose-free capsule and gelatin-free capsule could address excipient restrictions and support vegetarian or religiously compliant markets.

These changes are commercially useful but generally weak as stand-alone patent concepts. They become more defensible when combined with a distinct composition, manufacturing process, stability profile, or bioavailability result.

What patents protect Zarontin and ethosuximide products?

The original composition-of-matter protection for ethosuximide is long expired. Zarontin therefore does not have the type of active-ingredient patent barrier associated with a recently approved small molecule. Current competition is primarily governed by FDA approval status, manufacturing capability, product quality, supply, and any formulation-specific intellectual property.

Orange Book and listed patent position

The FDA Orange Book is the controlling source for approved drug products, therapeutic equivalence evaluations, and any listed patents for applicable products.[3] Legacy ethosuximide products generally do not present a meaningful active-ingredient patent barrier. A current commercial diligence review should distinguish:

1. The reference product’s listed patents, if any.
2. Generic product approvals and therapeutic-equivalence codes.
3. Any later patents covering a reformulated product.
4. Patent applications directed to taste masking, liquid stability, packaging, or manufacturing.

A new patent would not restore exclusivity to the old ethosuximide molecule. It could protect a specific formulation or delivery system if the claims satisfy novelty, nonobviousness, written-description, enablement, and other applicable requirements.

What patent claims could support a reformulated Zarontin product?

The strongest claim categories are likely to be:

• Composition claims covering a defined ethosuximide-excipient ratio
• Taste-masked liquid compositions
• Sugar-free or preservative-free formulations
• Low-impurity or improved-stability formulations
• Unit-dose packaging systems
• Dosing devices calibrated for pediatric administration
• Manufacturing processes that improve content uniformity
• Specific particle-size or suspension attributes
• Combination claims linking formulation and container closure

Broad claims such as “ethosuximide with a sweetener” would face substantial prior-art risk. Narrower claims tied to unexpected stability, palatability, dissolution, or dose-uniformity results are more commercially relevant.

When does Zarontin lose exclusivity and what is the generic entry risk?

Zarontin has already moved beyond its original exclusivity period. Generic ethosuximide products are available, and generic entry risk is therefore established rather than prospective. FDA-approved generic capsules and oral solutions can compete through therapeutic-equivalence pathways where the relevant products meet regulatory requirements.[3][4]

Exclusivity category	Zarontin assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the primary commercial protection for the legacy product
Pediatric exclusivity	Any historical period has expired
Active ingredient patent	Expired or no longer commercially controlling
Formulation exclusivity	Product-specific; no broad current barrier assumed
Generic entry	Established
Biosimilar risk	Not applicable
Paragraph IV risk	Relevant only to any later listed patent, not to the legacy molecule generally

A generic entrant could target the same capsule strength and oral-solution concentration. The principal barriers are formulation development, analytical method validation, stability data, manufacturing scale, controlled-substance or prescription-drug compliance where applicable, and commercial access.

Which companies are challenging Zarontin in the generic market?

Generic competition is product- and time-specific. Companies with FDA-approved ethosuximide products may include established generic manufacturers and specialty suppliers, but the FDA’s current Approved Drug Products with Therapeutic Equivalence Evaluations database should be used for the live manufacturer list.[3]

The competitive field typically includes:

• Large generic manufacturers with broad pharmacy distribution
• Specialty manufacturers focused on neurology
• Contract manufacturers supplying private-label products
• Authorized generic or branded-generic distributors
• Compounding pharmacies serving local demand, where legally permitted

The commercial risk is higher for a new entrant pursuing standard capsules because manufacturing is relatively conventional and substitution is straightforward. A differentiated liquid, unit-dose format, or pediatric device could face less direct substitution if no therapeutically equivalent product matches the same formulation and presentation.

How strong is the patent estate for a new ethosuximide formulation?

A new ethosuximide formulation could have moderate formulation-patent potential but low molecule-level protection. Patent strength depends on technical differentiation and the quality of comparative data.

Strategy	Patent potential	Commercial attractiveness	Main weakness
Sugar-free solution	Moderate	High in pediatrics	Substitution and prior-art risk
Preservative-free unit dose	Moderate	Moderate to high	Packaging cost
Taste-masked solution	Moderate to strong if data-supported	High	Palatability claims can be difficult to prove
Gelatin-free capsule	Low to moderate	Moderate	Easy design-around
Lactose-free capsule	Low to moderate	Moderate	Limited willingness to pay
Extended-release formulation	Moderate to strong	Uncertain	Absence-seizure dosing may not support complexity
Pediatric dosing device	Moderate	Moderate	Device competition and low pricing
New salt or prodrug	Potentially strong	Uncertain	Development and regulatory burden

The strongest portfolio would combine formulation claims with process claims, packaging claims, and method-of-use claims tied to a specific patient population or administration advantage. Method-of-use protection alone would be difficult because ethosuximide’s primary use is established.

What FDA regulatory pathway applies to a new Zarontin formulation?

A conventional generic capsule or oral solution would generally proceed through an abbreviated new drug application if the applicant can demonstrate pharmaceutical equivalence, bioequivalence where required, quality, and manufacturing compliance.[4]

A materially different product may require a 505(b)(2) application. This pathway could be relevant to:

• A novel delivery system
• A new dosage form
• A modified-release product
• A different concentration with a clinically meaningful administration advantage
• A formulation supported partly by published literature or the reference product

The regulatory route affects patent strategy. A 505(b)(2) applicant may generate its own Orange Book-listed patents for the approved formulation, method of use, or delivery system. A Paragraph IV certification could arise if the applicant challenges listed patents associated with a later reference product.

What commercial opportunities exist for Zarontin excipients?

Excipient suppliers can capture value without owning the ethosuximide product. The most attractive opportunities are excipient systems that solve pediatric formulation problems and can be qualified across multiple anticonvulsant products.

High-value excipient categories

Excipient opportunity	Use in ethosuximide product	Commercial value
Pediatric taste-masking system	Reduce bitterness and aftertaste	High
Sugar-free sweetener system	Replace sucrose	High
Preservative system	Protect multidose liquid	Moderate to high
Suspending and viscosity system	Improve dose uniformity	Moderate
Solubilizer	Maintain clear liquid	Moderate
Buffer system	Control pH and stability	Moderate
Coated capsule shell	Gelatin-free or colorant-reduced capsule	Moderate
Moisture-control packaging	Improve shelf life	Moderate
Unit-dose oral syringe	Improve pediatric dosing	Moderate to high

An excipient supplier should avoid selling a generic single-ingredient substitution without performance data. A complete platform that includes taste masking, preservative compatibility, stability, and dosing-device compatibility creates stronger customer lock-in.

How does Zarontin compare with competing absence-seizure treatments?

Zarontin competes in a narrower therapeutic segment than broad-spectrum antiseizure medicines. Ethosuximide is associated with absence seizures, while valproate and lamotrigine may be selected when patients have mixed seizure types or require broader coverage.[5]

Product	Primary positioning	Excipient opportunity
Zarontin ethosuximide	Absence seizures	Pediatric liquid and taste masking
Valproate products	Broad seizure coverage	Sugar-free and modified-release liquids
Lamotrigine	Broad use with titration constraints	Dispersible and orally disintegrating formats
Levetiracetam	Broad seizure coverage	High-volume pediatric liquid platforms

Zarontin’s narrow indication limits total market size but increases the value of formulation convenience. A child who requires a liquid may remain on therapy for years, making taste, dosing accuracy, and supply continuity commercially important.

What manufacturing and IP barriers affect a new product?

Manufacturing barriers are manageable but not trivial. The oral solution requires validated control of assay, impurities, pH, viscosity, microbial limits, preservative effectiveness, and container compatibility. The capsule requires blend uniformity, dissolution control, capsule-shell qualification, and stability under humidity exposure.

The most important IP barriers are prior art and design-around risk. Excipients used in oral liquids are often well established, which makes broad formulation claims vulnerable. A stronger strategy is to create a proprietary excipient combination with demonstrated unexpected performance and to protect the product through multiple claim types.

Supply-chain risks include:

• Single-source flavors
• Colorant restrictions by market
• Gelatin supply and certification
• Preservative availability
• Pharmaceutical-grade sweetener qualification
• Packaging-component shortages
• Variability in natural or complex flavors

A commercial launch should prioritize excipient qualification and dual sourcing before filing. A patented formulation that cannot be manufactured consistently has limited value.

What revenue exposure and launch scenarios exist?

Zarontin is a mature, niche product. Revenue exposure is concentrated in absence-seizure prescriptions, pediatric neurology, and the oral-solution segment. Public product-level revenue may not be separately disclosed by the marketing company, so exact Zarontin sales should not be inferred from broader corporate reporting.

Generic launch scenarios

Standard generic capsule launch: High substitution risk, low differentiation, and likely price pressure.

Generic oral-solution launch: Moderate opportunity. The entrant must match taste, stability, concentration, and supply performance.

Sugar-free pediatric solution: Higher differentiation and potential formulary value, particularly if the product has an easy-to-use dosing device.

Preservative-free unit-dose product: Niche opportunity with institutional and specialty-pharmacy potential but higher packaging costs.

505(b)(2) taste-masked product: Potentially stronger intellectual-property position and greater pricing flexibility, offset by clinical, regulatory, and commercial development costs.

Key Takeaways

• Zarontin contains ethosuximide and is marketed primarily as a 250 mg capsule and 250 mg/5 mL oral solution.
• The active ingredient and original exclusivity position are mature; generic entry is already established.
• The oral solution offers the clearest commercial opportunity because pediatric palatability, sugar content, preservatives, and dosing accuracy affect adherence.
• Sugar-free, taste-masked, preservative-free, and unit-dose formulations are the most credible lifecycle strategies.
• Excipients such as lactose, gelatin, sucrose, colorants, and parabens create opportunities for differentiated replacement systems.
• Broad ethosuximide formulation patents would face prior-art and design-around risk.
• A stronger patent estate would combine composition, manufacturing, packaging, device, and formulation-performance claims.
• Biosimilar risk does not apply because ethosuximide is a small molecule.
• A standard generic capsule is commercially exposed to rapid substitution and price erosion.
• A pediatric 505(b)(2) product could support better differentiation if it demonstrates meaningful improvements in taste, dosing, stability, or adherence.

FAQs

Is Zarontin oral solution sugar-free?

No. FDA labeling identifies sucrose as an inactive ingredient in the marketed oral solution.[1] A sugar-free ethosuximide liquid would represent a potential lifecycle and pediatric-formulation opportunity.

Does Zarontin contain lactose?

The capsule formulation includes lactose according to public labeling.[1] The oral solution is a separate formulation and should be assessed independently for excipient content.

Can a generic manufacturer patent a new ethosuximide formulation?

Yes. A generic manufacturer or other sponsor may seek patents covering a novel composition, manufacturing method, delivery system, packaging configuration, or approved method of use. The claims must protect a specific innovation rather than the expired ethosuximide molecule.

Is a biosimilar possible for Zarontin?

No. Biosimilars apply to biological products. Ethosuximide is a conventional small-molecule drug and competes through generic-drug pathways.

What is the best commercial excipient opportunity for ethosuximide?

A sugar-free, taste-masked pediatric oral solution with reliable multidose stability and an accurate oral syringe offers the strongest combined formulation and commercial rationale.

References

1. U.S. Food and Drug Administration. (n.d.). Zarontin (ethosuximide) prescribing information. Pfizer Laboratories.

2. National Library of Medicine. (n.d.). DailyMed: Zarontin, ethosuximide capsule and oral solution. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process for generic drugs. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

5. National Institute for Health and Care Excellence. (2022). Epilepsies in children, young people and adults: Diagnosis and management. NICE guideline NG217. https://www.nice.org.uk/guidance/ng217